- Notification that Quarterly Report will be submitted late (NT 10-Q)
May 12 2009 - 2:36PM
Edgar (US Regulatory)
|
SEC
FILE NUMBER
000-52871
|
|
|
CUSIP
NUMBER
452530
10 1
|
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 12b-25
NOTIFICATION OF LATE
FILING
(Check one):
¨
Form 10-K
¨
Form 20-F
¨
Form 11-K
x
Form 10-Q
¨
Form 10-D
¨
Form N-SAR
¨
Form N-CSR
For
Period Ended:
March 31,
2009
|
|
|
¨
|
|
Transition
Report on Form 10-K
|
¨
|
|
Transition
Report on Form 20-F
|
¨
|
|
Transition
Report on Form 11-K
|
¨
|
|
Transition
Report on Form 10-Q
|
¨
|
|
Transition
Report on Form N-SAR
|
For the
Transition Period Ended: ____________________
Read Instruction (on back page)
Before Preparing Form. Please Print or Type.
Nothing in this form shall be
construed to imply that the Commission has verified any information contained
herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART I — REGISTRANT
INFORMATION
Immunosyn
Corporation
Full Name
of Registrant
N/A
Former
Name if Applicable
4225
Executive Square, Suite 260
Address
of Principal Executive Office
(Street and
Number)
La Jolla,
CA 92037
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
|
|
(a) The
reason described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense
|
x
|
|
|
(b) The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or
Form N-CSR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject
distribution report on Form 10-D, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due date;
and
|
|
|
|
(c) The
accountant’s statement or other exhibit required by Rule 12b-25(c)
has been attached if
applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR,
or the transition report or portion thereof, could not be filed within the
prescribed time period.
Immunosyn
Corporation is seeking the extension due to its inability to complete the
financial statements and related discussion and analysis for the fiscal quarter
ended March 31, 2009 in a timely manner as a result of not having sufficient
resources to devote thereto.
.
PART IV — OTHER
INFORMATION
|
|
|
|
(1)
|
|
Name
and telephone number of person to contact in regard to this
notification
|
|
|
|
|
|
|
Douglas
A. McClain,
Jr.
(858)
200-2320
|
|
|
|
(Name)
(Area
Code) (Telephone Number)
|
|
|
|
|
|
(2)
|
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). Yes
x
No
¨
|
|
|
|
|
|
|
|
(3)
|
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? Yes
¨
No
x
|
|
|
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be
made.
|
Immunosyn
Corporation
(Name of
Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
Date:
May 12,
2009
|
By:
|
/s/
Douglas McClain, Jr.
|
|
|
|
Douglas
McClain, Jr.
Chief
Financial and Accounting
Officer
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the statement is signed
on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative’s authority to sign on behalf
of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or
omissions of fact constitute Federal Criminal Violations (See 18 U.S.C.
1001).